VYNE Therapeutics (VYNE) Return on Capital Employed Growth (1y) (2019 - 2026)
VYNE Therapeutics (VYNE) Return on Capital Employed Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -3,457.00 |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -3,238.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,238.00 |
| Jun 30, 2025 | -5,539.00 |
| Mar 31, 2025 | -5,700.00 |
| Dec 31, 2024 | -1,948.00 |
| Sep 30, 2024 | 13,932.00 |
| Jun 30, 2024 | 10,133.00 |
| Mar 31, 2024 | 6,818.00 |
| Dec 31, 2023 | 4,200.00 |
| Dec 31, 2022 | -2,967.00 |
| Dec 31, 2021 | 25,012.00 |
| Sep 30, 2021 | 21,888.00 |
| Jun 30, 2021 | 14,325.00 |
| Mar 31, 2021 | -3,607.00 |
| Dec 31, 2020 | -15,887.00 |
| Sep 30, 2020 | -17,769.00 |
| Jun 30, 2020 | -13,948.00 |
| Mar 31, 2020 | -12,322.00 |
| Dec 31, 2019 | -10,671.00 |
| Sep 30, 2019 | -7,145.00 |
| Jun 30, 2019 | -5,657.00 |